Background. Asymptomatic bacteriuria in pregnant women can contribute to urological and gestational complications. Antibiotic therapy is recommended in patients with 105 CFU/mL and above in the urine. However, choosing antimicrobial therapy is challenging for those with 103104 CFU/mL. Aim. To assess the effectiveness of Superlymph combined with phytotherapy in pregnant women with asymptomatic bacteriuria. Materials and methods. Pregnant women aged 21 to 38 with asymptomatic bacteriuria (bacterial count of 103104 CFU/mL), comparable in age, reproductive history, and extragenital comorbidities, were divided into three groups. In group 1 (32 subjects), Superlymph and a herbal medicine containing centaury, lovage root, and rosemary leaves were used. In group 2 (33 subjects), only the herbal medicinal product was used. In group 3 (35 subjects), the above drug products were not used. The patients received the herbal medicinal product containing centaury, lovage root, and rosemary leaves 2 tablets TID for 14 days. Superlymph was administered intravaginally (1 suppository [10 units] BID for 10 days). A follow-up urine culture for groups 1 and 2 was taken 23 weeks after the completion of therapy, and for patients of group 3, 23 weeks after the previous culture. A routine general clinical assessment of pregnant women was performed. Statistical analysis was carried out using the Statistica 12.0 software. Results. Patients of the main group that received the peptide-cytokine and herbal medicinal products had the most significant improvement compared with pregnant women of other groups, as shown by complete eradication from the urinary tract of Escherichia coli, improved urinary laboratory tests, cytology, and fewer gestational complications. Premature onset of labor was significantly less common (6-fold) in patients of the main group versus controls, who refused the proposed therapy for asymptomatic (moderate) bacteriuria. Conclusion. The addition of peptide-cytokine agent Superlymph increases the treatment effectiveness in pregnant women with asymptomatic bacteriuria.
Background. The high contagiousness and susceptibility of a pregnant woman's body to a new coronavirus infection requires study not only of etiopathogenesis, but also of developing methods to prevent the development of this disease. Aim. To evaluate the preventive effectiveness of the use of a drug containing recombinant interferon alfa-2b (IFN-a2b) and an antioxidant complex in pregnant women during their stay in the family focus of a new coronavirus infection. Materials and methods. 75 pregnant women were under observation, in whose family there were patients infected with the virus that causes a new coronavirus infection. Treatment of sick relatives was carried out at home, as the disease in them proceeded in an uncomplicated form. The main group was formed by 37 pregnant women who treated the nasal mucosa with a preparation containing recombinant IFN-a2b in the amount of 5000 IU and an antioxidant complex (alpha-tocopherol acetate, citric and benzoic acids). The comparison group was formed by 38 pregnant women who did not use any drugs for prophylactic purposes. All patients observed generally accepted rules of personal hygiene and behavior. The duration of prophylactic use of the indicated medicinal product depended on obtaining a negative result for the causative agent of a new coronavirus disease, an infected family member. A smear from the nasopharynx and oropharynx was examined to detect SARS-CoV-2 RNA by PCR once every 57 days. Results. COVID-19 vaccination did not exclude infection with the SARS-CoV-2. Preventive treatment of the nasal mucosa with an IFN-a2b containing drug reduced the risk of infection with this viral agent in vaccinated patients who were in household contact with a patient with COVID-19 by 6 times. Asymptomatic and mild course of a new coronavirus infection was observed in 3 (25%) and 7 (58.3%) patients of 12 infected women from the main group and in 8 (22.9%) and 18 (51.4%) patients of 35 infected women from the comparison group, respectively. Further local use of the drug containing recombinant IFN-a2b and an antioxidant complex contributed to a decrease in the duration of infection and the course of the disease. Progression of COVID-19 was observed in unvaccinated patients with concomitant somatic pathology (diabetes mellitus, iron deficiency anemia, cardiovascular diseases, etc.): 2 (16.7%) and 9 (25.7%) people in groups, respectively. Conclusion. The use of recombinant IFN-a2b with an antioxidant complex in pregnant women with a family focus of new coronavirus infection is clinically appropriate and highly effective.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.